<DOC>
	<DOCNO>NCT01411332</DOCNO>
	<brief_summary>1 . Delivery direct hypofractionated target ( HT ) radiotherapy ( RT ) tumor boost dominant tumor lesion prostate identify multiparametric MRI increase tumor eradication prostate . 2 . Biomarker expression level differ multiparametric MRI define region high risk harbor tumor determine outcome . 3 . 10-15 % men undergo RT Circulating DNA tumor cell ( CTC ) relate adverse treatment outcome . 4 . Quality life differ significantly treatment arm . 5 . Prostate cancer-related anxiety reduce HTIMRT arm , patient aware dominant tumor target high radiation dose .</brief_summary>
	<brief_title>A Phase III Trial Hypofractionated External Beam Image-Guided Highly Targeted Radiotherapy : The HEIGHT Trial</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>A. Biopsy confirm adenocarcinoma prostate . B. T1T3a disease base digital rectal exam . 1 . T1a permit peripheral zone biopsy positive . 2 . T3a disease base MRI acceptable . C. No evidence metastasis clinical criterion available radiographic test . D. Gleason score 68 . E. Patients Gleason score 8 must offer long term androgen deprivation therapy ( ADT ) refuse treatment 46 ( ±2 month ) month ( short term ADT ) permit protocol . Gleason score ≥ 8 patient recommend receive short term ADT conjunction RT . When give , ADT recommend begin fiducial marker placement , applicable ; however , ADT permit start two month prior sign consent . 1 . Patients Gleason score 8 disease must &lt; 40 diagnostic tumor tissue involve tumor . 2 . Patients Gleason score ≤7 may treat 46 ( ±2 month ) month ADT . F. PSA ≤100 ng/mL within 3 month enrollment . If PSA 100 drop ≤100 antibiotic , acceptable enrollment . G. If PSA &gt; 15 ng/ml ≥ Gleason 8 disease , bone scan obtain ≤4 month enrollment without evidence metastasis . A questionable bone scan acceptable plain xrays , CT and/or MRI negative metastasis . H. No previous pelvic radiotherapy I . No previous history radical/total prostatectomy ( suprapubic prostatectomy acceptable ) J . No concurrent , active malignancy , nonmetastatic skin cancer early stage chronic lymphocytic leukemia ( welldifferentiated small cell lymphocytic lymphoma ) . If prior malignancy remission ≥ 5 year patient eligible . K. Identifiable multiparameter functional MRI define tumor lesion lesion use 1.5T 3.0T MRI ( 3.0T preferable ) , total volume &lt; 33 % prostate within 3 month prior enrollment . a. Multiparametric functional include diffusion weight imaging ( DWI ) prostate pelvis require prior protocol consideration L. Ability understand willingness sign write informed consent document M. Zubrod performance status &lt; 2 ( Karnofsky Eastern Cooperative Oncology Group ( ECOG ) performance status may use estimate Zubrod ) N. Willingness fill quality life/psychosocial form . O . Age ≥35 ≤85 year . P. Serum testosterone within 40 % normal assay limit ( e.g. , x=0.4*lower assay limit x=.04*upper assay limit + upper assay limit ) , , take within 4 month enrollment . Patients start ADT prior sign consent require serum testosterone level prior signing consent ; , serum testosterone prior fiducial marker placement recommend . Q. Serum liver function test ( LFTs ) take within 3 month enrollment . R. Complete blood count take within 3 month enrollment . Exclusion Criteria A . Previous pelvic radiotherapy . B . Previous history radical prostatectomy . C. Concurrent , active malignancy , nonmetastatic skin cancer early stage chronic lymphocytic leukemia ( welldifferentiated small cell lymphocytic lymphoma ) . If prior malignancy remission &lt; 5 year patient eligible D. Not willing fill quality life/psychosocial questionnaire .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Adenocarcinoma</keyword>
</DOC>